Daily Sepsis Research Analysis
Analyzed 101 papers and selected 3 impactful papers.
Summary
Two mechanistic studies uncover mitochondrial drivers of lung injury in sepsis/ARDS—linking SERPINE1 to ferroptosis via a NAD/NADH–Sirt3 axis and IL-6/STAT3 to fibroblast OXPHOS dysfunction and AP-1 activation—while a large multicenter cohort shows SOFA-2 modestly improves sepsis identification and mortality prediction over SOFA-1. Together, these works advance precision endotyping and pragmatic bedside risk stratification.
Research Themes
- Mitochondrial dysfunction and ferroptosis in sepsis-induced lung injury
- Cytokine signaling (IL-6/STAT3) shaping fibroblast phenotypes and fibrosis
- Updating sepsis organ dysfunction scoring (SOFA-2) for improved identification and prognosis
Selected Articles
1. SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD
SERPINE1 was markedly upregulated in ARDS patients, ARDS mouse lungs, and LPS-treated alveolar type II cells and correlated with disease severity. Genetic or pharmacologic SERPINE1 inhibition reduced lung injury and ferroptosis (decreasing ACSL4/ALOX12 and restoring SLC7A11/GPX4/FTH1). Mechanistically, SERPINE1 disrupted mitochondrial NAD/NADH–Sirt3 signaling, identifying a metabolically driven ferroptosis pathway.
Impact: This study uncovers a previously unrecognized upstream regulator of ferroptosis in ARDS, linking inflammation to mitochondrial redox imbalance and epithelial injury. It offers a concrete, targetable axis (SERPINE1–NAD/NADH–Sirt3) for therapy.
Clinical Implications: Although preclinical, targeting SERPINE1/PAI-1 or preserving mitochondrial NAD/NADH–Sirt3 balance may mitigate epithelial ferroptosis and improve outcomes in sepsis-related ARDS. It supports exploration of PAI-1 inhibitors or metabolic modulators.
Key Findings
- SERPINE1 expression is elevated in ARDS patients, ARDS mouse models, and LPS-stimulated AT2 cells and correlates with disease severity.
- SERPINE1 knockout or pharmacologic inhibition reduces lung injury, lowers ferroptosis markers (ACSL4, ALOX12), and restores SLC7A11, GPX4, and FTH1.
- Mechanistically, SERPINE1 disrupts mitochondrial NAD/NADH–Sirt3 signaling, linking inflammatory signaling to ferroptosis-driven epithelial injury.
Methodological Strengths
- Integrated human datasets, in vivo ARDS models, and in vitro AT2 cell systems
- Convergent genetic (deficiency) and pharmacologic inhibition to test causality
Limitations
- Preclinical models (LPS/animal) may not fully recapitulate human sepsis-ARDS heterogeneity
- Specificity and safety of systemic PAI-1 inhibition in human ARDS remain untested
Future Directions: Validate SERPINE1–NAD/NADH–Sirt3 axis in diverse human ARDS endotypes; test PAI-1 inhibitors or metabolic modulators in translational models and early-phase clinical trials.
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is characterized by alveolar epithelial injury, inflammatory dysregulation, oxidative stress, and impaired repair capacity. Ferroptosis, an iron-dependent and lipid peroxidation-driven form of regulated cell death, has emerged as a pathogenic driver of ARDS; however, the upstream molecular regulators that initiate ferroptotic signaling in alveolar epithelial cells remain poorly defined. SERPINE1 (PAI-1), a mediator of inflammatio
2. IL-6/STAT3 signaling drives mitochondrial oxidative phosphorylation dysfunction and AP-1 activation in fibroblasts during sepsis-induced lung injury.
Single-cell profiling and functional assays show fibroblasts transition to inflammatory and profibrotic states in sepsis, with heightened IL-6/STAT3 signaling linked to impaired OXPHOS, increased mitochondrial ROS, and AP-1 activation. Clinically relevant glucocorticoids attenuated injury and fibrosis by suppressing the IL-6/STAT3–OXPHOS–AP-1 axis in experimental models.
Impact: Defines a fibroblast-centered metabolic and transcriptional pathway in sepsis lung injury with direct therapeutic modulation by glucocorticoids, bridging single-cell endotyping to actionable interventions.
Clinical Implications: Supports targeting IL-6/STAT3-driven mitochondrial dysfunction in fibroblasts; provides mechanistic rationale for timing and selection of glucocorticoids in sepsis-associated ALI/fibrosis.
Key Findings
- Fibroblasts shift to inflammatory and profibrotic states during sepsis with increased IL-6/STAT3 activity.
- IL-6/STAT3 signaling associates with impaired mitochondrial OXPHOS, higher mitochondrial ROS, and AP-1 activation driving profibrotic protein expression.
- Dexamethasone and methylprednisolone attenuate lung injury and fibrosis by suppressing the IL-6/STAT3–OXPHOS–AP-1 axis in experimental sepsis ALI.
Methodological Strengths
- Single-cell RNA-seq integrated with in vivo and in vitro functional validation
- Therapeutic testing with clinically used glucocorticoids to demonstrate modifiability
Limitations
- Preclinical models may not capture the full heterogeneity of human sepsis-induced ALI
- Causal hierarchy between IL-6/STAT3 activation and downstream AP-1 targets in human tissue requires further validation
Future Directions: Translate fibroblast IL-6/STAT3–OXPHOS signatures to human endotypes; evaluate targeted IL-6/STAT3 or mitochondrial modulators alongside glucocorticoids in precision trials.
Sepsis-induced acute lung injury (ALI) and early fibrotic remodeling remain major clinical challenges with limited effective treatments. In this study, we systematically investigated the role of fibroblasts in sepsis-associated lung injury and fibrosis using single-cell RNA sequencing combined with functional validation. We found that fibroblast states shifted from a resting state toward pro-inflammatory and pro-fibrotic phenotypes during sepsis, including Glycoprotein-producing Fibroblast
3. The new SOFA for sepsis identification and mortality prediction: a multicenter cohort study.
Across 11,669 ICU admissions with external validation in 29,811 MIMIC-IV patients, SOFA-2 identified more sepsis cases than SOFA-1 (49.0% vs. 45.5; P < 0.001) with substantial diagnostic agreement and modestly better ICU mortality discrimination. Patients identified by SOFA-2 had more advanced organ dysfunction profiles, and the Sepsis-3 threshold of ≥2 did not require recalibration.
Impact: This large multicenter analysis with external validation directly informs bedside sepsis identification, supporting adoption of SOFA-2 without changing Sepsis-3 thresholds.
Clinical Implications: ICUs can implement SOFA-2 to slightly increase sepsis case capture and improve mortality risk stratification while maintaining continuity with Sepsis-3 criteria.
Key Findings
- SOFA-2 identified a larger sepsis population than SOFA-1 (49.0% vs. 45.5%; P < 0.001) with substantial diagnostic agreement.
- SOFA-2 provided modestly improved discrimination for ICU mortality compared with SOFA-1.
- Organ dysfunction profiles were more advanced in SOFA-2-identified patients, and a SOFA ≥2 threshold did not require recalibration.
Methodological Strengths
- Large multicenter cohort with external validation in an independent database (MIMIC-IV)
- Direct head-to-head comparison with organ dysfunction profiling and mortality prediction
Limitations
- Retrospective design subject to residual confounding and coding variability
- Generalizability beyond ICU populations and across health systems requires further evaluation
Future Directions: Prospective implementation studies to assess workflow impact and patient-centered outcomes using SOFA-2; evaluate performance in non-ICU and emergency settings.
BACKGROUND: The Sequential Organ Failure Assessment (SOFA) score is central to Sepsis-3 criteria. SOFA-2 updates thresholds and incorporates contemporary organ support practices, but its impact on sepsis identification and outcome prediction remains uncertain. This study aimed to compare the diagnostic yield and prognostic performance of SOFA-2 versus SOFA-1 for sepsis identification in critically ill adults. METHODS: We conducted a retrospective multicenter cohort study of 11,669 ICU adm